News

Inspirata Hosts Fireside Chat on the Future of Pathology in a Post-COVID-19 World

Cancer informatics and digital pathology solution provider Inspirata is setting its sights on the post-COVID-19 future. Following the drastic social distancing measures implemented across the world, Inspirata announced its COVID-19 Free Remote Pathology Initiative in March, which allows healthcare institutions...

MedPharm Develops Model to Support Coronavirus Pharmaceutical Development

MedPharm, a leading clinical development organization in topical and transdermal drug delivery, has expanded its innovative testing models to support pharmaceutical development programs targeting Coronavirus treatments. These models allow companies to assess therapeutic effectiveness in nasal, airway (bronchial), and...

ARTES Biotech to Develop VLP SARS-CoV-2 Vax Candidates

ARTES Biotechnology, a biotech company specializing in process development for recombinant vaccines, entered development of SARS-CoV-2 vaccine candidates based on its virus-like particle (VLP) based platform technologies METAVAX and SplitCore. METAVAX is a platform for the development of vaccines built...

Sino-Pack2020 and PACKINNO2020 will be further postponed from June 2020 to March 2021

Postponement of the 27th China International Exhibition on Packaging Machinery & Materials (Sino-Pack2020) cum China (Guangzhou) International Exhibition on Packaging Products (PACKINNO2020) Since the occurrence of COVID-19, we have been closely monitoring the situation. On 8th April 2020, the State...

Bio-Rad Begins Shipping COVID-19 Antibody Test

Bio-Rad Laboratories has launched its SARS-CoV-2 Total Ab test, a blood-based immunoassay kit to help determine if an individual has developed antibodies to SARS-CoV-2, the virus associated with COVID-19 disease. Bio-Rad has applied for Emergency Use Authorization offered by...

Q BioMed, Mannin Research Accelerate COVID-19 Response Initiatives

Q BioMed Inc., and its technology partner, Mannin Research, are accelerating the rapid development of novel drugs for the treatment of life-threatening complications caused by COVID-19 and other viral infections. The drug program is being evaluated by government programs...

Cytovance and Akshaya Bio Announce Collaboration Agreement of Therapeutics for Treatment of Coronavirus and Hepatitis B Virus

Cytovance Biologics, a contract development and manufacturing organization (CDMO) and a subsidiary of the Shenzhen Hepalink Pharmaceutical Group Co., Ltd., has entered into a collaboration agreement with Akshaya Bio, a Canadian development stage biotechnology company to provide rapid access...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read